Cell Bio Human Tech terminates treasury stock trust, acquires 74,956 shares worth 500 million KRW, representing 0.8% of outstanding shares, minor impact
The company terminated its treasury stock acquisition trust agreement with Daishin Securities on June 9, 2026, and now directly holds 74,956 shares acquired at a total cost of approximately 500 million KRW.
The acquisition represents 0.8% of total outstanding shares of 9,337,513 and less than 1% of the market capitalization of approximately 50.3 billion KRW, making it a small-scale buyback.
While treasury stock acquisition is generally seen as a shareholder-friendly move, the small scale limits its immediate impact on stock price and shareholder value.
The treasury shares may be used for future cancellation or employee compensation, but further shareholder return policies are needed.
[AI Summary]Cell Bio Human Tech completed its 500 million KRW treasury stock trust, acquiring 74,956 shares or 0.8% of outstanding shares, a minor buyback with limited effect on shareholder value. The direct holding of treasury shares does not significantly alter capital efficiency.